Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy.

OBJECTIVE It is thought as a consequence of continuous replication, HIV-1 has acquired an optimal fitness state and that suboptimal antiretroviral therapy selects for drug resistant variants which show impaired fitness in the absence of the drug. In this paper we studied the evolution and fitness of viral populations appearing in a patient who received protease monotherapy. METHODS Two factors contributing to fitness, drug resistance and protease catalytic activity, were studied at the enzymatic and virological level. RESULTS The first drug resistant viral variants that were selected in vivo harboured one to three protease substitutions. These mutants showed reduced protease activity and consequently a reduction in viral replication capacity. During continued in vivo replication of these viruses in the presence of the drug, novel variants harbouring additional substitutions in the viral protease appeared. These variants did not display any further increase in drug resistance but demonstrated clearly increased protease activity. Consequently the replication capacity of these viruses was raised to a level at which they replicated better than the original wild-type virus. CONCLUSION This study indicates that the viral population in the patient does not have to represent the fittest possible variants, and thus antiretroviral therapy may drive the viral population first through a lower fitness level and then to a higher fitness level.

[1]  S. Gulnik,et al.  Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. , 1995, Biochemistry.

[2]  F. Mammano,et al.  Loss of Viral Fitness Associated with Multiple Gag and Gag-Pol Processing Defects in Human Immunodeficiency Virus Type 1 Variants Selected for Resistance to Protease Inhibitors In Vivo , 1998, Journal of Virology.

[3]  S. Elena,et al.  Exponential increases of RNA virus fitness during large population transmissions. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[4]  S. J. Clark,et al.  High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. , 1993, Science.

[5]  A. Perelson,et al.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.

[6]  J. Falloon,et al.  Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites , 1997, Journal of virology.

[7]  W. Keulen,et al.  Reduced replication of 3TC‐resistant HIV‐1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. , 1996, The EMBO journal.

[8]  E. Domingo,et al.  Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy , 1995, Journal of virology.

[9]  D. Richman,et al.  Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients , 1996, Journal of virology.

[10]  C. Boucher,et al.  Anti-CD4 therapy for AIDS suggested by mathematical models , 1996, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[11]  D. Ho,et al.  Ordered accumulation of mutations in HIV protease confers resistance to ritonavir , 1996, Nature Medicine.

[12]  R. Weiss,et al.  Recombinant CD4-selected human immunodeficiency virus type 1 variants with reduced gp120 affinity for CD4 and increased cell fusion capacity , 1991, Journal of virology.

[13]  S. Elena,et al.  Extreme fitness differences in mammalian and insect hosts after continuous replication of vesicular stomatitis virus in sandfly cells , 1995, Journal of virology.

[14]  Y. Lin,et al.  Proteolytic processing mechanisms of a miniprecursor of the aspartic protease of human immunodeficiency virus type 1. , 1994, Biochemistry.

[15]  S. Elena,et al.  Basic concepts in RNA virus evolution , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  J. Sninsky,et al.  Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection , 1994, Journal of clinical microbiology.

[17]  N. Shen,et al.  Extensive polymorphisms observed in HIV–1 clade B protease gene using high–density oligonucleotide arrays , 1996, Nature Medicine.

[18]  J. Coffin,et al.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.

[19]  C. Boucher,et al.  Sensitive procedure for the amplification of HIV-1 RNA using a combined reverse-transcription and amplification reaction. , 1995, BioTechniques.

[20]  L. M. Mansky,et al.  Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase , 1995, Journal of virology.

[21]  Anthony S. Fauci,et al.  HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease , 1993, Nature.

[22]  R. Colonno,et al.  Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J. Louis,et al.  Kinetics and mechanism of autoprocessing of human immunodeficiency virus type 1 protease from an analog of the Gag-Pol polyprotein. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Coffin,et al.  Genetic diversity and evolution of retroviruses. , 1992, Current topics in microbiology and immunology.

[25]  P D Griffiths,et al.  Population dynamics of HIV within an individual after treatment with zidovudine , 1991, AIDS.

[26]  A. Perelson,et al.  HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.

[27]  R M Stroud,et al.  Domain flexibility in retroviral proteases: structural implications for drug resistant mutations. , 1998, Biochemistry.

[28]  J. E. Bouma,et al.  Evolution of a bacteria/plasmid association , 1988, Nature.

[29]  A S Perelson,et al.  Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase , 1996, Journal of virology.

[30]  S. Gulnik,et al.  In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine , 1993, Antimicrobial Agents and Chemotherapy.

[31]  J. Erickson,et al.  Structural mechanisms of HIV drug resistance. , 1996, Annual review of pharmacology and toxicology.

[32]  Q. Sattentau,et al.  Dissociation of gp120 from HIV-1 virions induced by soluble CD4. , 1990, Science.

[33]  D. Lamarre,et al.  Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors , 1996, Journal of virology.

[34]  Ashley T. Haase,et al.  Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS , 1993, Nature.

[35]  E. Domingo,et al.  RNA virus mutations and fitness for survival. , 1997, Annual review of microbiology.

[36]  B. Levin,et al.  Adaptation to the fitness costs of antibiotic resistance in Escherichia coli , 1997, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[37]  R. Lenski,et al.  Dynamics of adaptation and diversification: a 10,000-generation experiment with bacterial populations. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[38]  R de Boer,et al.  Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215 , 1997, Journal of virology.

[39]  E. Furfine,et al.  Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors , 1995, Journal of virology.

[40]  C. Boucher,et al.  Replication of a pre-existing resistant HIV-1 subpopulation in vivo after introduction of a strong selective drug pressure. , 1996, Antiviral therapy.

[41]  F. Mammano,et al.  Resistance-Associated Loss of Viral Fitness in Human Immunodeficiency Virus Type 1: Phenotypic Analysis of Protease andgag Coevolution in Protease Inhibitor-Treated Patients , 1998, Journal of Virology.

[42]  J S Sinsheimer,et al.  In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects , 1996, Journal of virology.

[43]  M. Salimans,et al.  Rapid and simple method for purification of nucleic acids , 1990, Journal of clinical microbiology.

[44]  S. Paulous,et al.  Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug. , 1996, The Journal of general virology.

[45]  D. Ho,et al.  A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. , 1995, The New England journal of medicine.

[46]  J. Ermolieff,et al.  Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in vivo. , 1997, Biochemistry.

[47]  C. Boucher,et al.  Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[48]  L. M. Lehman,et al.  A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. , 1995, The New England journal of medicine.

[49]  Martin A. Nowak,et al.  Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.

[50]  R. Siliciano,et al.  Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection , 1997, Nature.

[51]  John M. Leonard,et al.  Genotypic Changes in Human Immunodeficiency Virus Type 1 Associated with Loss of Suppression of Plasma Viral RNA Levels in Subjects Treated with Ritonavir (Norvir) Monotherapy , 1998, Journal of Virology.